Rockville, June 05, 2023 (GLOBE NEWSWIRE) -- The recent research analysis by Fact.MR on the global market global cell line development provides a thorough overview of the industry’s product, end-user, and region categories. It also offers comprehensive details on important players and the crucial tactics they are turning to for gaining an upper hand over their competitors.
Fact.MR – A Market Research and Competitive Intelligence Provider The global cell line development market stands at US$ 4.97 billion in 2023 and is projected to reach a valuation of US$ 8.2 billion by the end of 2033. Over the next ten years, Fact.MR’s research projects global demand for cell line development to rise at 5.1% CAGR.
For more insights into the Market, Request a Sample of this Report –
https://www.factmr.com/connectus/sample?flag=S&rep_id=180
Key Driving Forces Accelerating the Market Growth
- There is a rising demand for biologics, such as antibodies, vaccines, and recombinant proteins, in countries such as the US. Cell line development plays a crucial role in the production of these biologics, leading to increased adoption of cell line development technologies.
- The prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders has been increasing in various geographies. Cell line development enables the production of therapeutic proteins and monoclonal antibodies used in the treatment of these diseases, driving market growth.
- North America is a hub for biotechnology research, with several academic institutions, research organizations, and biopharmaceutical companies leading the way. The continuous advancements in biotechnology, including genetic engineering and gene editing techniques, contribute to the growth of the cell line development market.
- Currently, demand for cell line development in the US accounts for more than 90% share of the North American regional market.
- There have been significant technological advancements in cell line development methods, such as single-cell cloning, high-throughput screening, and automation. These innovations enhance the efficiency, productivity, and reproducibility of cell line development processes, attracting more users and driving market growth.
- Countries such as the US has a well-established regulatory framework for biopharmaceuticals, providing clear guidelines for cell line development and ensuring the safety and efficacy of the produced biologics. A favorable regulatory environment fosters market growth by promoting research and development activities.
Vital indicators shaping the future of the industry
- The growing demand for biologics, such as monoclonal antibodies, vaccines, and cell-based therapies, is a significant driver for the cell line development market in North America. Biologics offer targeted and personalized treatment options, and cell lines play a crucial role in their production.
- The development of advanced cell line engineering technologies, such as CRISPR/Cas9, recombinant DNA technology, and high-throughput screening methods, is driving innovation in the field. These technologies enable more efficient and precise cell line development, accelerating the overall process.
- Personalized medicine, which involves tailoring treatments to individual patients based on their genetic makeup, is gaining traction in North America. Cell lines are instrumental in developing personalized therapies, as they can be genetically modified to mimic specific patient characteristics and diseases.
- Collaborations between pharmaceutical companies, research institutions, and contract development and manufacturing organizations (CDMOs) are on the rise. These partnerships help in leveraging expertise, resources, and infrastructure to accelerate cell line development and bring products to market faster.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=180
Challenges hindering the market growth
- The use of certain cell lines, especially those derived from embryonic or fetal tissues, raises ethical concerns and may face regulatory restrictions. Stricter regulations and ethical considerations can limit the availability and use of specific cell lines, impacting research and development in the field.
- Intellectual property rights and patent disputes can hinder the growth of the cell line development market. Legal battles and uncertainties surrounding cell line ownership and licensing can create barriers for companies and researchers, affecting the commercialization and utilization of specific cell lines.
Strategies for manufacturers/suppliers to scale in the market
- Manufacturers/suppliers can broaden their product and service portfolio to cater to a wider range of customer needs. This may include offering a diverse range of cell lines, specialized cell culture media, cell line characterization services, genetic stability testing, and other related products or services.
- For instance, In January 2023, Berkeley Lights Inc. announced the launch of a new optofluidic system for cell line development.
- Allocating resources to research and development activities is crucial for manufacturers/suppliers to stay at the forefront of innovation. Investing in advanced technologies, process optimization, and genetic engineering methods can lead to the development of novel and improved cell lines, enhancing their competitiveness in the market.
Key Companies Profiled
- Thermo Fisher Scientific Inc.
- WuXi AppTec Co. Ltd.
- Corning Incorporated
- Selexis SA
- Sigma-Aldrich Corporation
- Sartorius AG
- General Electric Company
- Lonza Group Ltd.
- Abzena plc.
- American Type Culture Collection Inc.
Explore Our Safe & Secure Payment Options for Quick Buy –
https://www.factmr.com/checkout/180
Key Segments of Cell Line Development Industry Research
- By Product Type :
- Immunotherapy Cell Lines
- Ion Channel Cell Lines
- GPCR Cell Lines
- Cell Signaling Pathway Cell Lines
- Gene Knockout Cell Lines
- Cancer Cell Lines
- Other
- By Application :
- Drug Discovery & Development
- Basic Research
- Toxicity Screening
- Biopharmaceutical Production
- Drug Screening
- Tissue Engineering
- Forensic Testing
- By End User :
- Biopharmaceutical Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Forensic Science Laboratories
- Food & Beverage Companies
- Diagnostic Centers
- Others
- By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Check out more related studies published by Fact.MR Research:
Epidermal Cell sheets Market: Rising demand for epidermal care, driven by sensitive skin ailments, is a key factor spurring revenue of epidermal cell sheet market.
Drug Discovery Services Market Outlook: The drug discovery services market is forecasted to reach US$ 50 Billion by 2032, up from US$ 19 Billion in 2022, at a CAGR of 10.1%. A Y-o-Y growth rate of nearly 12% is expected for the market in 2022. As of 2021, the market was valued at US$ 17 Billion.
Rheumatoid Arthritis Stem Cell Therapy Market: The global rheumatoid arthritis stem cell therapy market account for a share of USD 23.42 Billion in 2022. The market is anticipated to surpass the valuation of USD 33.30 Billion by end of the forecast period i.e. 2032. The rheumatoid arthritis stem cell market is expected to grow with a CAGR of 4.5 %.
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Author: Mr. Shambhu Nath Jha
Email : shambhu@factmr.com
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube
